---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-040988"
form_type: "8-K"
ticker: "ABSI"
cik: "0001672688"
company_name: "Absci Corp"
filed_at: "2023-12-07T23:59:59+00:00"
generated_at: "2026-06-07T16:15:22.694680+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Absci appoints Sir Menelas Pangalos (AstraZeneca EVP) to Board, effective Jan 1, 2024

## Summary
- Board size fixed at 7 directors; Pangalos appointed as Class II director until 2026 annual meeting.
- Initial option grant to purchase 106,200 shares, vesting monthly over 3 years from Grant Date.
- Annual cash retainer of $47,500 for Board and Compensation Committee service.
- Sir Pangalos currently serves as Executive Vice-President, R&D BioPharmaceuticals at AstraZeneca.

## SEC filing metadata
- accession: 0001628280-23-040988
- form_type: 8-K
- ticker: ABSI
- cik: 0001672688
- company_name: Absci Corp
- filed_at: 2023-12-07T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1672688/000162828023040988/0001628280-23-040988-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1672688/000162828023040988/absc-20231205.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-040988
- JSON: https://secwatch.observer/filing/0001628280-23-040988.json
- Plain text: https://secwatch.observer/filing/0001628280-23-040988.txt

## Key facts
- Executive change
  Professor Sir Menelas Pangalos was appointed as Director at Absci Corp.
  - Action: appointed
  - Role: Director
  source text: On December 5, 2023, the Board of Directors (the “Board”) of Absci Corporation (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Professor Sir Menelas Pangalos to the Board effective January 1, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1672688/000162828023040988/0001628280-23-040988-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.